# Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

> **NCT05930275** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 1200 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05930275
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930275, "Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05930275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*